Biocytogen and Merck to advance antibody-conjugated lipid-based delivery solutions

Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services

Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases

Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity

FDA approves Coya Therapeutics’ trial of COYA 302 for ALS

As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya

Healthium and C-CAMP launch innovations program for surgical and medical technologies

Eris Lifesciences receives ANVISA approval for sterile injectable facility

Enanta files patent infringement suit against Pfizer

The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists

Vivo Bio Tech secures pre-clinical testing contract valued at Rs.10.75 Cr

Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies

FDA lifts hold on Rocket Pharma's gene therapy trial

Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort

Tonix receives FDA approval of Tonmya for treatment of fibromyalgia

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants